Federated Hermes, Inc. Karyopharm Therapeutics Inc. Transaction History

Federated Hermes, Inc.

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	BUY	$2.48 - $5.93 $95,740 - $228,927	38,605 New	38,605 $131,000
Q2 2022 Aug 15, 2022	BUY	$4.15 - $8.37 $20,505 - $41,356	4,941 New	4,941 $22,000
Q2 2020 Aug 13, 2020	SELL	$16.6 - $25.25 $428,578 - $651,904	-25,818 Closed	0 $0
Q1 2020 May 13, 2020	SELL	$14.38 - $27.72 $11.4 Million - $21.9 Million	-791,443 Reduced 96.84%	25,818 $496,000
Q4 2019 Feb 14, 2020	BUY	$9.23 - $19.67 $7.54 Million - $16.1 Million	817,261 New	817,261 $15.7 Million
Q2 2019 Aug 14, 2019	SELL	$4.32 - $6.43 $396,498 - $590,158	-91,782 Closed	0 $0
Q1 2019 May 10, 2019	SELL	$4.12 - $10.25 $830,662 - $2.07 Million	-201,617 Reduced 68.72%	91,782 $536,000
Q4 2018 Feb 13, 2019	SELL	$8.2 - $16.95 $20,131 - $41,612	-2,455 Reduced 0.83%	293,399 $2.75 Million
Q3 2018 Nov 13, 2018	BUY	$17.03 - $21.18 $5 Million - $6.21 Million	293,408 Added 11995.42%	295,854 $5.04 Million
Q2 2018 Aug 10, 2018	BUY	$12.0 - $19.88 $26,772 - $44,352	2,231 Added 1037.67%	2,446 $42,000
Q1 2018 May 09, 2018	BUY	$9.92 - $17.25 $2,132 - $3,708	215 New	215 $3,000

57.6M

258K

81.2K

Ticker KPTI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 79,806,600
Market Cap $51.1M
Description
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company discovers, develops, and commercializes novel and Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and in...

Get notified when there are updates to the investment portfolio of Federated Hermes, Inc., based on Form 13F filings with the SEC.

Stay updated on Federated Hermes, Inc. with notifications on news.